Fig. 1 · Structure

Documents & Downloads

Sesamolin

Cat. No. A12123 CAS 526-07-8
Sesamolin is a lignan isolated from sesame oil. It is found that sesamolin inhibited lipid peroxidation in rat liver and kidney.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Sesamolin Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Sesamolin from 3 published references. In vitro models include h-CYP46A1-Neuro-2a. In vivo models include C57BL/6J mice.

Sesamolin In Vitro Studies

In h-CYP46A1-Neuro-2a cells, Sesamolin was tested at 20 μM for 24 h. Treatment significantly reduced CYP46A1 protein levels by 57.1% compared with the control group. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Sesamolin reduces CYP46A1 protein levels in cultured cells

Cell-based study · h-CYP46A1-Neuro-2a [1]

In h-CYP46A1-Neuro-2a cells, Sesamolin treatment at 20 μM for 24 h significantly reduced CYP46A1 protein levels by 57.1% compared with the control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CYP46A1 protein levelsCYP46A1 protein levels 20 μM for 24 h: CYP46A1 protein levels reduced by 57.1% compared with the control group[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 μM
Exposure duration
24 h
Method
replacing the medium with a serum-free medium containing sesame ligands
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Sesamolin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Material and methods > Cell culture and treatment (S65); Results > Effects of sesame lignans on CYP46A1 protein expression in h-CYP46A1-Neuro-2a (S117, S118)

CYP46A1 protein levels: CYP46A1 protein levels; comparator: control group — Material and methods > Cell culture and treatment (S65); Results > Effects of sesame lignans on CYP46A1 protein expression in h-CYP46A1-Neuro-2a (S118)

Sesamolin In Vivo Studies

In C57BL/6J mice fed an HF-HF diet, oral Sesamolin at 60 mg/kg significantly altered 16 serum metabolite biomarkers compared with the untreated HF-HF group, with 14 upregulated and 2 downregulated. In the body weight study, the same treatment significantly decreased final body weight gain compared with the untreated HF-HF group. In female BALB/c nude mice inoculated with Ishikawa cells, oral Sesamolin at 30 mg/kg and 60 mg/kg showed a suppressive effect on EC progression, as assessed by xenograft size and weight, compared with the control group. [2,3]

Sesamolin alters serum metabolic profiles in mice

Animal study · C57BL/6J mice [2]

In C57BL/6J mice fed an HF-HF diet, oral Sesamolin treatment at 60 mg/kg significantly altered 16 serum metabolite biomarkers compared with the untreated HF-HF group. Of these metabolites, 14 were upregulated and 2 were downregulated.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
serum metabolic profilesReported result 60 mg/kg twice a day from week 9 to week 12: a total of 16 serum metabolite biomarkers were found as significant alterations by sesamolin treatment, in which 14 metabolites were upregulated and 2 metabolites were downregulated in the sesamolin-treated group, compared with the HF-HF group.[2]

Conditions shared by the study groups

Route
orally administrated
Treatment course
twice a day from week 9 to week 12
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Sesamolin 60 mg/kgHF-HF group (mice fed with HF-HF diet without treatment)60 mg/kg twice a day from week 9 to week 12: a total of 16 serum metabolite biomarkers were found as significant alterations by sesamolin treatment, in which 14 metabolites were upregulated and 2 metabolites were downregulated in the sesamolin-treated group, compared with the HF-HF group.[2]
Sesamolin 60 mg/kg
Model: C57BL/6J mice
Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Sesamolin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.5. Sesamolin Alters Serum Metabolome in HF-HF Diet-Fed Mice (S36, S40); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S49, S56)

serum metabolic profiles: serum metabolic profiles; comparator: HF-HF group (mice fed with HF-HF diet without treatment) — 2. Results > 2.5. Sesamolin Alters Serum Metabolome in HF-HF Diet-Fed Mice (S36, S40); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S56)

Sesamolin 60 mg/kg · 2. Results > 2.5. Sesamolin Alters Serum Metabolome in HF-HF Diet-Fed Mice (S40); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S56)

Sesamolin suppresses Ishikawa xenograft progression in mice

Animal study · female BALB/c nude mice; subcutaneously inoculated with 2.0 × 106 Ishikawa cells per mouse; n = 5 [3]

In female BALB/c nude mice subcutaneously inoculated with Ishikawa cells, oral Sesamolin treatment at 30 mg/kg and 60 mg/kg showed a suppressive effect on EC progression, as assessed by xenograft size and weight, compared with the control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
weight of xenograftsReported result 30 mg/kg and 60 mg/kg: suppressive role of sesamolin on EC progression, as indicated by the evaluation of the size and weight of xenografts.[3]

Conditions shared by the study groups

Route
orally administered
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Sesamolin 30 mg/kg and 60 mg/kgcontrol group30 mg/kg and 60 mg/kg: suppressive role of sesamolin on EC progression, as indicated by the evaluation of the size and weight of xenografts.[3]
Sesamolin 30 mg/kg and 60 mg/kg
Model: female BALB/c nude mice; subcutaneously inoculated with 2.0 × 106 Ishikawa cells per mouse; n = 5
Reported limits: Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: Sesamolin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > In vivo study (S78, S79, S80, S82); Results > Sesamolin directly targeted MYH14 to attenuate EC progression (S154, S155); Fig. 6 legend (S225, S226)

weight of xenografts: weight of xenografts; comparator: control group — Materials and methods > In vivo study (S82); Results > Sesamolin directly targeted MYH14 to attenuate EC progression (S154); Fig. 6 legend (S225)

Sesamolin 30 mg/kg and 60 mg/kg · Materials and methods > In vivo study (S82); Results > Sesamolin directly targeted MYH14 to attenuate EC progression (S154)

Sesamolin reduces body weight gain in mice

Animal study · C57BL/6J mice [2]

In C57BL/6J mice fed an HF-HF diet, oral Sesamolin treatment at 60 mg/kg significantly decreased final body weight gain compared with the untreated HF-HF group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Final body weight gainReported result 60 mg/kg twice a day from week 9 to week 12: compared with mice in the HF-HF group, the body weight gain of mice in the sesamolin-treated group decreased significantly at the end of the experiment.[2]

Conditions shared by the study groups

Route
orally administrated
Treatment course
twice a day from week 9 to week 12
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Sesamolin 60 mg/kgHF-HF group (mice fed with HF-HF diet without treatment)60 mg/kg twice a day from week 9 to week 12: compared with mice in the HF-HF group, the body weight gain of mice in the sesamolin-treated group decreased significantly at the end of the experiment.[2]
Sesamolin 60 mg/kg
Model: C57BL/6J mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Sesamolin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Sesamolin Suppresses Obesity and Metabolic Disorders in HF-HF Diet-Fed Mice (S2); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S49, S56); Figure 1 legend (S95)

Final body weight gain: Final body weight gain; comparator: HF-HF group (mice fed with HF-HF diet without treatment) — 2. Results > 2.1. Sesamolin Suppresses Obesity and Metabolic Disorders in HF-HF Diet-Fed Mice (S2); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S56); Figure 1 legend (S95)

Sesamolin 60 mg/kg · 2. Results > 2.1. Sesamolin Suppresses Obesity and Metabolic Disorders in HF-HF Diet-Fed Mice (S2); 4. Experimental Section > 4.1. Animal Experimental Design and Sample Collection (S56)

Specifications

Manufacturer Adooq Bioscience
CAS Number 526-07-8
Formula C20H18O7
Molecular Weight 370.35
SMILES
C1[C@H]2[C@H](CO[C@@H]2OC3=CC4=C(C=C3)OCO4)[C@H](O1)C5=CC6=C(C=C5)OCO6

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Sesamolin Research References

  1. [1] Du J, Chen X, Zhao Y, et al. Characterization of three naturally occurring lignans, sesamol, sesamolin, and sesamin, as potent inhibitors of human cytochrome P450 46A1: Implications for treating excitatory neurotoxicity. Front Pharmacol (2022). PMID: 36483743 DOI: 10.3389/fphar.2022.1046814 Source material
  2. [2] Yu J, Sun H, Yang Y, et al. Sesamolin Alleviates Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites in High-Fat and High-Fructose Diet-Fed Mice. Int J Mol Sci (2022). PMID: 36430326 DOI: 10.3390/ijms232213853 Source material
  3. [3] Lin Y, Chen X, Lin L, et al. Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling. Cell Mol Biol Lett (2024). PMID: 38698330 DOI: 10.1186/s11658-024-00583-9 Source material

Added to your cart

View Cart Checkout
Loading...